Transport of Metabolites between the Mesophyll and Epidermis of Commelina cyanea R. Br.

1984 ◽  
Vol 11 (2) ◽  
pp. 59
Author(s):  
N Thorpe ◽  
F.L Milthorpe

The concentrations of 10 major metabolites in the epidermis were one-third to one-half of those in the mesophyll when the stomata were open. I4CO2 was supplied to the leaf and the radioactivity contained in glucose, sucrose, sugar phosphates, malate, glycine, serine and alanine, and the ethanolinsoluble HC1-hydrolysable fraction was followed for 2 h in both the mesophyll and epidermis. The net fluxes from mesophyll to epidermis were in the range 0.7-4 nmol m-2 s-I when the leaf was actively photosynthesizing and fell to near zero or became negative with no net photosynthesis. Fluxes were largely independent of concentration differences, which did not vary greatly from initial values. Although the amounts reaching the epidermis greatly exceeded those fixed from C02 in situ, available evidence suggests that the epidermis may have the capacity to supply its own carbon needs; the carbon imported no doubt supplies extra substrates and energy and may influence the flux of K+ ions through the guard-cell membranes. Efflux curves indicated that one-half to three-quarters of the soluble substances in the epidermis diffused readily from it but only about 10% of those in the mesophyll diffused rapidly.

2020 ◽  
Author(s):  
Felix Kaspar ◽  
Peter Neubauer ◽  
Anke Kurreck

<div>Ask what an equilibrium can do for you:</div><div>Hydrolysis of pentose-1-phosphates leads to an apparent increase of the equilibrium conversion in nucleoside phosphorolysis reactions. This information can be leveraged via equilibrium thermodynamics to determine the hydrolysis kinetics of in situ generated sugar phosphates, which are known to be elusive and difficult to quantify.<br></div>


2020 ◽  
Vol 45 (16) ◽  
pp. 10089-10103 ◽  
Author(s):  
Dilip Ramani ◽  
Yadvinder Singh ◽  
Robin T. White ◽  
Matthew Wegener ◽  
Francesco P. Orfino ◽  
...  

2021 ◽  
Author(s):  
Yuxuan Zhang ◽  
Jie Liu ◽  
Yunzhao Mo ◽  
Zetao Chen ◽  
Taoliang Chen ◽  
...  

Abstract BACKGROUND: Mesenchymal stem cells (MSCs) have emerged as putative therapeutic tools due to their intrinsic tumour tropism, anti-tumour, and immunoregulatory properties. The limited passage and self-differentiation abilities of MSCs in vitro hinder preclinical studies of mesenchymal stem cells, and makes the MSC-based treatment of tumours lack a stable, uniform, and homogeneous source of cells. In this study, we focused on the safety of immortalised mesenchymal stem cells (im-MSCs) and, for the first time, studied the feasibility of im-MSCs as candidates for the treatment of glioma.METHODS: The im-MSCs were constructed by the lentiviral transfection of genes, and the proliferative capacity of immortalised MSCs and the proliferative phenotype of MSCs and MSCs co-cultured with glioma cells (U87) were measured using CCK-8 and EdU assays. After long-term culture, karyotype analysis of im-MSCs was conducted. In addition, the tumourigenicity of engineered MSCs was evaluated using soft agar cloning assays. Moreover, the engineered cells were injected into the brain of female BALB/c nude mice. Finally, the cell membranes of im-MSCs were labelled with DIO or DIR to detect their ability to be taken by glioma cells and target in situ gliomas using an IVIS system.RESULTS: Im-MSCs expressed CD73, CD90, CD105, CD29, and CD44 but did not express CD45, CD34, CD14, CD11b, or CD31. Engineered MSCs maintained the ability to differentiate into mesenchymal lineages in vitro. Im-MSCs showed stronger proliferative capacity than unengineered MSCs without colony formation in soft agar, no tumourigenicity in the brain, and normal chromosomes. MSCs or im-MSCs co-cultured with U87 cells showed enhanced proliferation ability, but did not show malignant characteristics in soft agar cloning experiments. Immortalised cells continued to express homing molecules. The cell membranes of im-MSCs were taken up by glioma cells and targeted in situ gliomas in vivo.CONCLUSIONS: Im-MSCs are promising candidates for cellular anti-glioma therapy. Im-MSCs provide a safe, adequate, quality-controlled, and continuous source of cells or cell membranes for the treatment of glioma.


Sign in / Sign up

Export Citation Format

Share Document